Clinical Trial

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.
Trial Details
NCT Number NCT07701941
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Enrollment 220 participants
Start Date 2026-08-03
Primary Completion 2031-01-01 (estimated)
Study Completion 2032-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-14